LC-MS/MS determination of dutasteride and its major metabolites in human plasma. 2021

Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
Department of Bioanalysis and Drugs Analysis, Doctoral School, Medical University of Warsaw, 61 Żwirki i Wigury, 02-091 Warsaw, Poland; Łukasiewicz Research Network, Industrial Chemistry Institute, 8 Rydygiera, 01-793 Warsaw, Poland.

Dutasteride is a specific and selective inhibitor of both 5α-reductase isoforms used mainly in benign prostatic hyperplasia and lower urinary tract symptoms. Although the drug is extensively metabolized in humans, data on the concentrations of its main metabolites are lacking. There is also a lack of data on dutasteride stability in frozen plasma samples. Our method was used to determine dutasteride and its active metabolites: 4'-hydroxydutasteride, 6β-hydroxydutasteride, and 1,2-dihydrodutasteride in plasma after a single administration of 0.5 mg of dutasteride. We also assessed the long-term stability (two years in the freezer) of dutasteride in clinical samples. The developed method covered the range of 0.1-3.5 ng/mL for dutasteride and 0.08-1.2 ng/mL for 1,2-dihydrodutasteride, 4'-hydroxydutasteride, 6β-hydroxydutasteride. It was proved to be reliable as it met all validation criteria required by the European Medicine Agency for bioanalytical methods. 4'-hydroxydutasteride and 1,2-dihydrodutasteride concentrations in plasma were higher than 6β-hydroxydutasteride. Dutasteride was stable in the freezer for up to 2 years in clinical samples. Thus within 1014 days of storage (below - 65 °C), samples can be reanalyzed without the risk of unreliable results.

UI MeSH Term Description Entries
D008297 Male Males
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068538 Dutasteride A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA. 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one,Avodart,GG 745,GG-745,GG745,GI198745,745, GG
D001378 Azasteroids Steroidal compounds in which one or more carbon atoms in the steroid ring system have been substituted with nitrogen atoms. 17- Azasteroids,4- Azasteroids,Azasteroid,17 Azasteroids,4 Azasteroids,Azasteroids, 17-,Azasteroids, 4-
D053719 Tandem Mass Spectrometry A mass spectrometry technique using two (MS/MS) or more mass analyzers. With two in tandem, the precursor ions are mass-selected by a first mass analyzer, and focused into a collision region where they are then fragmented into product ions which are then characterized by a second mass analyzer. A variety of techniques are used to separate the compounds, ionize them, and introduce them to the first mass analyzer. For example, for in GC-MS/MS, GAS CHROMATOGRAPHY-MASS SPECTROMETRY is involved in separating relatively small compounds by GAS CHROMATOGRAPHY prior to injecting them into an ionization chamber for the mass selection. Mass Spectrometry-Mass Spectrometry,Mass Spectrometry Mass Spectrometry,Mass Spectrometry, Tandem
D058891 5-alpha Reductase Inhibitors Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE. 3-Oxo-5-alpha-Steroid 4-Dehydrogenase Inhibitor,5-alpha Reductase Inhibitor,Steroid 5-alpha-Reductase Inhibitor,Testosterone 5-alpha-Reductase Inhibitor,3-Oxo-5-alpha-Steroid 4-Dehydrogenase Inhibitors,Steroid 5-alpha-Reductase Inhibitors,Testosterone 5-alpha-Reductase Inhibitors,3 Oxo 5 alpha Steroid 4 Dehydrogenase Inhibitor,3 Oxo 5 alpha Steroid 4 Dehydrogenase Inhibitors,4-Dehydrogenase Inhibitor, 3-Oxo-5-alpha-Steroid,4-Dehydrogenase Inhibitors, 3-Oxo-5-alpha-Steroid,5 alpha Reductase Inhibitor,5 alpha Reductase Inhibitors,5-alpha-Reductase Inhibitor, Steroid,5-alpha-Reductase Inhibitor, Testosterone,5-alpha-Reductase Inhibitors, Steroid,5-alpha-Reductase Inhibitors, Testosterone,Inhibitor, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase,Inhibitor, 5-alpha Reductase,Inhibitor, Steroid 5-alpha-Reductase,Inhibitor, Testosterone 5-alpha-Reductase,Inhibitors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase,Inhibitors, 5-alpha Reductase,Inhibitors, Steroid 5-alpha-Reductase,Inhibitors, Testosterone 5-alpha-Reductase,Reductase Inhibitor, 5-alpha,Reductase Inhibitors, 5-alpha,Steroid 5 alpha Reductase Inhibitor,Steroid 5 alpha Reductase Inhibitors,Testosterone 5 alpha Reductase Inhibitor,Testosterone 5 alpha Reductase Inhibitors

Related Publications

Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
June 2018, Bioanalysis,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
July 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
September 2016, Journal of chromatographic science,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
September 2015, Journal of chromatographic science,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
November 2007, Journal of pharmaceutical and biomedical analysis,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
December 2000, Journal of pharmaceutical and biomedical analysis,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
December 2017, Therapeutic drug monitoring,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
July 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
September 2003, Journal of pharmaceutical and biomedical analysis,
Elżbieta Gniazdowska, and Michał Kaza, and Katarzyna Buś-Kwaśnik, and Joanna Giebułtowicz
October 2018, Journal of pharmaceutical analysis,
Copied contents to your clipboard!